CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Mindfulness + Compassion Intervention (MC)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug3009 standard operating procedures Wiki 1.00
drug1497 Mindfulness Alone (MO) Intervention Wiki 1.00

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Preliminary Efficacy of a One-Session Mindfulness Telehealth Intervention for Loneliness

The primary aim of this study is to examine the efficacy of a one-session, hour-long HIPAA-compliant video platform-based mindfulness + compassion telehealth intervention on reducing feelings of loneliness during COVID-19 quarantine. Participants (n=120) currently isolating due to COVID-19 will be randomized to one of three interventions: (a) mindfulness + compassion (MC); (b) mindfulness alone (MO); and (c) waitlist control (WL). The investigators predict that participants in the active intervention groups (mindfulness or mindfulness + compassion) will show a significantly greater reduction in subjective feelings of loneliness at one week follow-up compared to those in the waitlist control group. Additionally, investigators predict that participants in the active intervention groups will show a significantly greater reduction in stress at one week follow-up compared to those in the waitlist control group. Last, investigators predict that participants in the mindfulness + compassion group will show a significantly greater reduction in subjective feelings of loneliness at the 2-week follow-up follow-up relative to those in the mindfulness only group.

NCT04414826 Loneliness Behavioral: Mindfulness Alone (MO) Intervention Behavioral: Mindfulness + Compassion Intervention (MC)

Primary Outcomes

Description: Change from baseline in self-reported feelings of loneliness and social isolation. Scores range from 8 to 32, with higher scores indicating higher levels of loneliness.

Measure: Revised University of California Los Angeles Loneliness Scale - 8 (ULS-8)

Time: Baseline (Day 0), one-week follow-up (Day 14), two-week follow-up (Day 21)

Secondary Outcomes

Description: Change from baseline in self-reported feelings of stress. Scores range from 0 to 40, with higher scores indicating more perceived stress.

Measure: Perceived Stress Scale (PSS)

Time: Baseline (Day 0), one-week follow-up (Day 14), two-week follow-up (Day 21)

Other Outcomes

Description: Change from baseline in self-reported anxiety symptoms. Scores range from 0 to 21, with higher scores indicating more severe anxiety.

Measure: Generalized Anxiety Disorder - 7 (GAD-7)

Time: Baseline (Day 0), one-week follow-up (Day 14), two-week follow-up (Day 21)

Description: Change from baseline in self-reported depressive symptoms. Scores range from 0 to 24, with higher scores indicating higher depressive symptom severity.

Measure: Personal Health Questionnaire Depression Scale - 8 (PHQ-8)

Time: Baseline (Day 0), one-week follow-up (Day 14), two-week follow-up (Day 21)

Description: Change from baseline in self-reported quality of life. Scores range from 0 to 48, with higher scores indicating better quality of life.

Measure: Brunnsviken Brief Quality of Life Scale (BBQ)

Time: Baseline (Day 0), one-week follow-up (Day 14), two-week follow-up (Day 21)


No related HPO nodes (Using clinical trials)